Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies
Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record for this completed Phase 1/2 isatuximab study is displayed, including its study design, eligibility criteria, treatment arms, outcome measures, locations, and supporting documents.SummaryDifference100%

- Check20 days agoChange DetectedThe footer now identifies the site revision as v3.8.0 instead of v3.7.2; the study page content remains unavailable.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces an NIH-wide transition and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence,” with both terms appearing during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check48 days agoChange DetectedThe study record page shows a 403 Forbidden message and a Home link instead of study details.SummaryDifference0.5%

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.